LON:IBAI

Imaging Biometrics Ltd., through its subsidiaries, provides clinical treatments to patients in the field of medical imaging diagnostics in the United Kingdom, China, European Union, South America, Australia, and the United States. It operates through Holding Company, Medical Software, Oral Gallium Maltolate (GaM), and Organ-on-a-chip segments. The company develops ready-to-use software applications for the healthcare industry comprising IB Clinic; IB Neuro, a MRI perfusion platform that generates quantitative relative cerebral blood volume maps; IB Delta Suite, an image processing tool kit containing fundamental capabilities designed for routine use in medical imaging including image subtraction, co-registration, and class map generation; and use to creates Delta T1 maps from conventional MR images. It also offers IB Nimble, for collaborative discussions for any complex disease or emergent healthcare setting; IB Rad Tech, that automates and simplifies complex imaging tasks; IB Diffusion, to analyze MR diffusion-weighted images; and IB DCE analyzes dynamic contrast-enhanced MRI images. In addition, the company provides IB ASL, a software solution that enables non-invasive, quantitative measurement of cerebral blood flow using MRI; Liver Surface Nodularity, an innovative imaging tool designed to non-invasively assess chronic liver disease using commonly acquired CT images; and StoneChecker, a medical software tool designed to aid clinical decision making by providing information about a patient’s kidney stone. The company was formerly known as IQ-AI Limited and changed its name to Imaging Biometrics Ltd. in May 2025. Imaging Biometrics Ltd. was incorporated in 1965 and is based in Saint Helier, Jersey.